{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:31:51Z","timestamp":1786480311487,"version":"build-2736575974"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/11\/66\/28982"],"award-info":[{"award-number":["PG\/11\/66\/28982"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Foundation of Oregon"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 DK115683"],"award-info":[{"award-number":["K23 DK115683"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2022,9,29]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n \n The highest fibroblast growth factor 23 (FGF23) quartile had impaired VO\n 2<\/jats:sub>\n Max and ventilatory exercise response patterns compared with the lowest FGF23 quartile.\n <\/jats:p>\n <\/jats:list-item>\n \n \n FGF23 was associated with changes in VO\n 2<\/jats:sub>\n Max in advanced CKD and after restitution of the failing kidney by transplantation.\n <\/jats:p>\n <\/jats:list-item>\n \n FGF23 was only associated with the progression of left ventricular mass index in patients with advanced CKD, however this association was lost after adjustment for dialysis status in the final model and was not associated after kidney transplantation in all models.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Fibroblast growth factor 23 (FGF23) is a bone-derived phosphatonin that is elevated in chronic kidney disease (CKD) and has been implicated in the development of cardiovascular disease. It is unknown whether elevated FGF23 in CKD is associated with impaired cardiovascular functional capacity, as assessed by maximum exercise oxygen consumption (VO\n 2<\/jats:sub>\n Max). We sought to determine whether FGF23 is associated with cardiovascular functional capacity in patients with advanced CKD and after improvement of VO\n 2<\/jats:sub>\n Max by kidney transplantation.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We performed secondary analysis of 235 patients from the Cardiopulmonary Exercise Testing in Renal Failure and After Kidney Transplantation (CAPER) cohort, which recruited patients with stage 5 CKD who underwent kidney transplantation or were waitlisted and hypertensive controls. All patients underwent cardiopulmonary exercise testing (CPET) and echocardiography and were followed longitudinally for 1 year after study enrollment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Patients across FGF23 quartiles differed in BMI (\n P<\/jats:italic>\n =0.004) and mean arterial pressure (\n P<\/jats:italic>\n <0.001) but did not significantly differ in sex (\n P<\/jats:italic>\n =0.5) or age (\n P<\/jats:italic>\n =0.08) compared with patients with lower levels of FGF23. Patients with higher FGF23 levels had impaired VO\n 2<\/jats:sub>\n Max (Q1: 24.2\u00b14.8 ml\/min per kilogram; Q4: 18.6\u00b15.2 ml\/min per kilogram;\n P<\/jats:italic>\n <0.001), greater left ventricular mass index (LVMI;\n P<\/jats:italic>\n <0.001), reduced HR at peak exercise (\n P<\/jats:italic>\n <0.001), and maximal workload (\n P<\/jats:italic>\n <0.001). Kidney transplantation conferred a significant decline in FGF23 at 2 months (\n P<\/jats:italic>\n <0.001) before improvement in VO\n 2<\/jats:sub>\n Max at 1 year (\n P<\/jats:italic>\n =0.008). Multivariable regression modeling revealed that changes in FGF23 was significantly associated with VO\n 2<\/jats:sub>\n Max in advanced CKD (\n P<\/jats:italic>\n <0.001) and after improvement after kidney transplantation (\n P<\/jats:italic>\n =0.006). FGF23 was associated with LVMI before kidney transplantation (\n P<\/jats:italic>\n =0.003), however this association was lost after adjustment for dialysis status (\n P<\/jats:italic>\n =0.4). FGF23 was not associated with LVMI after kidney transplantation in all models.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n FGF23 levels are associated with alterations in cardiovascular functional capacity in advanced CKD and after kidney transplantation. FGF23 is only associated with structural cardiac adaptations in advanced CKD but this was modified by dialysis status, and was not associated after kidney transplantation.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0002192022","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T16:00:11Z","timestamp":1657036811000},"page":"1529-1541","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["FGF23 and Cardiovascular Structure and Function in Advanced Chronic Kidney Disease"],"prefix":"10.34067","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4496-9967","authenticated-orcid":false,"given":"Arvin","family":"Halim","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather N.","family":"Burney","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1547-3041","authenticated-orcid":false,"given":"Xiaochun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7024-7103","authenticated-orcid":false,"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tomkins","sequence":"additional","affiliation":[{"name":"Biochemistry Department, Kettering General Hospital NHS Foundation Trust, Kettering, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Siedlecki","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3115-5000","authenticated-orcid":false,"given":"Tzong-shi","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahir","family":"Kalim","sequence":"additional","affiliation":[{"name":"Nephrology Division, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Thadhani","sequence":"additional","affiliation":[{"name":"Mass General Brigham, Harvard Medical School, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Moe","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.S.","family":"Ting","sequence":"additional","affiliation":[{"name":"Department of Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zehnder","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Department of Acute Medicine, North Cumbria University Hospital NHS Trust, Carlisle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Hiemstra","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of Cambridge; Clinical Trials Unit (CTU), Addenbrooke\u2019s Hospital, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","article-title":"Regulation of fibroblast growth factor-23 signaling by klotho","volume":"281","author":"Kurosu","year":"2006","journal-title":"J Biol Chem"},{"key":"B3-20250825","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.ki.5001788","article-title":"Post-transplant hypophosphatemia: Tertiary \u201chyper-phosphatoninism\u201d?","volume":"70","author":"Bhan","year":"2006","journal-title":"Kidney Int"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/TP.0b013e3181caeead","article-title":"Reduction in cardiovascular death after kidney transplantation","volume":"89","author":"Pilmore","year":"2010","journal-title":"Transplantation"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2353\/ajpath.2006.060329","article-title":"Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals","volume":"169","author":"Sitara","year":"2006","journal-title":"Am J Pathol"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2003.12.102","article-title":"FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa","volume":"314","author":"Shimada","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B8-20250825","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.111.053405","article-title":"Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23","volume":"125","author":"Lim","year":"2012","journal-title":"Circulation"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J Clin Invest"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","article-title":"The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study","volume":"152","author":"Parker","year":"2010","journal-title":"Ann Intern Med"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","article-title":"Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population","volume":"207","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"key":"B12-20250825","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","article-title":"Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community","volume":"205","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"key":"B13-20250825","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1007\/s00198-006-0154-6","article-title":"Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients","volume":"17","author":"Inaba","year":"2006","journal-title":"Osteoporos Int"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"572355","DOI":"10.3389\/fphys.2020.572355","article-title":"Cardiovascular functional changes in chronic kidney disease: Integrative physiology, pathophysiology and applications of cardiopulmonary exercise testing","volume":"11","author":"Lim","year":"2020","journal-title":"Front Physiol"},{"key":"B15-20250825","first-page":"1285","article-title":"Cardiopulmonary exercise testing and its application","volume":"93","author":"Albouaini","year":"2007","journal-title":"Heart"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/01.CIR.83.3.778","article-title":"Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure","volume":"83","author":"Mancini","year":"1991","journal-title":"Circulation"},{"key":"B17-20250825","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1164\/rccm.167.2.211","article-title":"ATS\/ACCP statement on cardiopulmonary exercise testing","volume":"167","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"B18-20250825","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","article-title":"ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)","volume":"46","author":"Hunt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B19-20250825","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/CIRCULATIONAHA.109.914788","article-title":"Cardiopulmonary exercise testing in the clinical evaluation of patients with heart and lung disease","volume":"123","author":"Arena","year":"2011","journal-title":"Circulation"},{"key":"B20-20250825","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199212173272504","article-title":"The prognostic value of exercise testing in patients with cystic fibrosis","volume":"327","author":"Nixon","year":"1992","journal-title":"N Engl J Med"},{"key":"B21-20250825","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1164\/rccm.200206-583OC","article-title":"Analysis of the factors related to mortality in chronic obstructive pulmonary disease: Role of exercise capacity and health status","volume":"167","author":"Oga","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"B22-20250825","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1161\/01.CIR.0000041428.99427.06","article-title":"Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death","volume":"106","author":"Gitt","year":"2002","journal-title":"Circulation"},{"key":"B23-20250825","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1378\/chest.116.2.355","article-title":"Cardiopulmonary exercise testing as a screening test for perioperative management of major surgery in the elderly","volume":"116","author":"Older","year":"1999","journal-title":"Chest"},{"key":"B24-20250825","doi-asserted-by":"crossref","first-page":"e64335","DOI":"10.1371\/journal.pone.0064335","article-title":"Reduced functional measure of cardiovascular reserve predicts admission to critical care unit following kidney transplantation","volume":"8","author":"Ting","year":"2013","journal-title":"PLoS One"},{"key":"B25-20250825","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/bja\/aeq128","article-title":"Impaired functional capacity is associated with all-cause mortality after major elective intra-abdominal surgery","volume":"105","author":"Wilson","year":"2010","journal-title":"Br J Anaesth"},{"key":"B26-20250825","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2013040348","article-title":"Functional cardiovascular reserve predicts survival pre-kidney and post-kidney transplantation","volume":"25","author":"Ting","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B27-20250825","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.jacc.2017.08.012","article-title":"Cardiopulmonary exercise testing: What is its value?","volume":"70","author":"Guazzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B28-20250825","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamacardio.2019.5738","article-title":"Cardiovascular functional reserve before and after kidney transplant","volume":"5","author":"Lim","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B29-20250825","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2215\/CJN.03670807","article-title":"Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle?","volume":"3","author":"Stenvinkel","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B30-20250825","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.jrn.2011.10.021","article-title":"Cardiovascular biomarkers in chronic kidney disease","volume":"22","author":"Park","year":"2012","journal-title":"J Ren Nutr"},{"key":"B31-20250825","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2215\/CJN.04470709","article-title":"Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function","volume":"4","author":"Burton","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B32-20250825","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/ki.1996.201","article-title":"Outcome and risk factors of ischemic heart disease in chronic uremia","volume":"49","author":"Parfrey","year":"1996","journal-title":"Kidney Int"},{"key":"B34-20250825","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1161\/CIR.0b013e31826fb946","article-title":"EACPR\/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations","volume":"126","author":"Guazzi","year":"2012","journal-title":"Circulation"},{"key":"B35-20250825","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1161\/01.CIR.0000136811.45524.2F","article-title":"Cardiopulmonary exercise testing: How do we differentiate the cause of dyspnea?","volume":"110","author":"Milani","year":"2004","journal-title":"Circulation"},{"key":"B36-20250825","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: A report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"B37-20250825","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1164\/ajrccm.167.10.950","article-title":"ATS\/ACCP statement on cardiopulmonary exercise testing","volume":"167","author":"Ross","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"B38-20250825","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.ajkd.2015.02.335","article-title":"Reduced cardiovascular reserve in chronic kidney failure: A matched cohort study","volume":"66","author":"Ting","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B39-20250825","doi-asserted-by":"crossref","first-page":"viii2","DOI":"10.1093\/ndt\/gfg1083","article-title":"Left ventricular hypertrophy: Why does it happen?","volume":"18","author":"London","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"B40-20250825","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ki.1996.355","article-title":"Cardiac and arterial interactions in end-stage renal disease","volume":"50","author":"London","year":"1996","journal-title":"Kidney Int"},{"key":"B41-20250825","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.cardfail.2020.09.477","article-title":"Fibroblast growth factor 23 and exercise capacity in heart failure with preserved ejection fraction","volume":"27","author":"Ghuman","year":"2021","journal-title":"J Card Fail"},{"key":"B42-20250825","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1152\/ajpendo.00596.2012","article-title":"FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy","volume":"304","author":"Touchberry","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B43-20250825","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00198-011-1838-0","article-title":"FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages","volume":"23","author":"Desjardins","year":"2012","journal-title":"Osteoporos Int"},{"key":"B44-20250825","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fendo.2018.00189","article-title":"FGF23 actions on target issues\u2014With and without klotho","volume":"9","author":"Richter","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B45-20250825","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11427-016-5089-3","article-title":"Mitochondrial Ca(2+) uptake in skeletal muscle health and disease","volume":"59","author":"Zhou","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B46-20250825","doi-asserted-by":"crossref","first-page":"565023","DOI":"10.3389\/fphys.2020.565023","article-title":"Mitochondrial dysfunction in kidney disease and uremic sarcopenia","volume":"11","author":"Takemura","year":"2020","journal-title":"Front Physiol"},{"key":"B47-20250825","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1021\/bi3015983","article-title":"Effect of calcium on the oxidative phosphorylation cascade in skeletal muscle mitochondria","volume":"52","author":"Glancy","year":"2013","journal-title":"Biochemistry"},{"key":"B48-20250825","first-page":"532","article-title":"Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease","volume":"6","author":"Yazdi","year":"2013","journal-title":"Int J Clin Exp Med"},{"key":"B49-20250825","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/TP.0000000000001155","article-title":"The risk of cardiovascular disease is not increasing over time despite aging and higher comorbidity burden of kidney transplant recipients","volume":"101","author":"Lam","year":"2017","journal-title":"Transplantation"},{"key":"B50-20250825","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/ndt\/gfu190","article-title":"Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD","volume":"29","author":"Di Marco","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B51-20250825","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/ehf2.13283","article-title":"Changes in left ventricular structure and function associated with renal transplantation: A systematic review and meta-analysis","volume":"8","author":"Pickup","year":"2021","journal-title":"ESC Heart Fail"},{"key":"B52-20250825","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2369-15-65","article-title":"Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: A controlled longitudinal study","volume":"15","author":"Hern\u00e1ndez","year":"2014","journal-title":"BMC Nephrol"},{"key":"B53-20250825","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/ndt\/gfv354","article-title":"Regression of asymptomatic cardiomyopathy and clinical outcome of renal transplant recipients: A long-term prospective cohort study","volume":"31","author":"Paoletti","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B54-20250825","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00467-008-0855-5","article-title":"Improved left ventricular mass index in children after renal transplantation","volume":"23","author":"Becker-Cohen","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"B55-20250825","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2215\/CJN.01400308","article-title":"Renal transplantation is not associated with regression of left ventricular hypertrophy: A magnetic resonance study","volume":"3","author":"Patel","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B56-20250825","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ekir.2017.05.007","article-title":"The association between fibroblast growth factor 23 and renal transplantation outcome is modified by follow-up duration and glomerular filtration rate assessment method","volume":"2","author":"Bienaim\u00e9","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B57-20250825","doi-asserted-by":"crossref","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","article-title":"FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis","volume":"289","author":"Coe","year":"2014","journal-title":"J Biol Chem"},{"key":"B58-20250825","doi-asserted-by":"crossref","first-page":"e2996","DOI":"10.1371\/journal.pone.0002996","article-title":"The ergogenic effect of recombinant human erythropoietin on VO2max depends on the severity of arterial hypoxemia","volume":"3","author":"Robach","year":"2008","journal-title":"PLoS One"},{"key":"B59-20250825","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/eurheartj\/ehx209","article-title":"Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints","volume":"40","author":"Rossignol","year":"2019","journal-title":"Eur Heart J"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0002192022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:02:58Z","timestamp":1786478578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0002192022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0002192022","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"2022-03-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}